Non-replicating Toxoplasma gondii reverses tumor-associated immunosuppression

OncoImmunology

Volumn 2, Issue 11, 2013, Pages

  Fox, Barbara A ^a   Sanders, Kiah L ^a   Bzik, David J ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Anticancer vaccines; Cancer immunotherapy; CD8+ T cells; Non replicating Toxoplasma gondii; Reversing tumor derived immunosuppression

Indexed keywords

ANTINEOPLASTIC AGENT; NON REPLICATING TOXOPLASMA GONDII URACIL; UNCLASSIFIED DRUG; URACIL DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUXOTROPHY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; MELANOMA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; TOXOPLASMA GONDII; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84892417026     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26296     Document Type: Article

References (10)

1. Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013; 39:61-73; PMID:23890064; http://dx.doi.org/10.1016/j. immuni.2013.07.005.
2. Gubbels MJ, Striepen B, Shastri N, Turkoz M, Robey EA. Class I major histocompatibility complex presentation of antigens that escape from the parasitophorous vacuole of Toxoplasma gondii. Infect Immun 2005; 73:703-11; PMID:15664908; http://dx.doi. org/10.1128/IAI.73.2.703-711.2005.
3. Denkers EY, Bzik DJ, Fox BA, Butcher BA. An Inside Job: Hacking Into JAK/STAT signaling Cascades by the Intracellular Protozoan Toxoplasma gondii. Infect Immun 2012; 80:476-82; PMID:22104110; http://dx.doi.org/10.1128/IAI.05974-11.
4. Koshy AA, Dietrich HK, Christian DA, Melehani JH, Shastri AJ, Hunter CA, Boothroyd JC. Toxoplasma co-opts host cells it does not invade. PLoS Pathog 2012; 8:e1002825; PMID:22910631; http://dx.doi. org/10.1371/journal.ppat.1002825.
5. Butcher BA, Fox BA, Rommereim LM, Kim SG, Maurer KJ, Yarovinsky F, Herbert DR, Bzik DJ, Denkers EY. Toxoplasma gondii rhoptry kinase ROP16 activates STAT3 and STAT6 resulting in cytokine inhibition and arginase-1-dependent growth control. PLoS Pathog 2011; 7:e1002236; PMID:21931552; http://dx.doi.org/10.1371/journal. ppat.1002236.
6. Fentress SJ, Behnke MS, Dunay IR, Mashayekhi M, Rommereim LM, Fox BA, Bzik DJ, Taylor GA, Turk BE, Lichti CF, et al. Phosphorylation of immunityrelated GTPases by a Toxoplasma gondii-secreted kinase promotes macrophage survival and virulence. Cell Host Microbe 2010; 8:484-95; PMID:21147463; http://dx.doi.org/10.1016/j.chom.2010.11.005.
7. Fox BA, Bzik DJ. De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondii. Nature 2002; 415:926-9; PMID:11859373; http://dx.doi. org/10.1038/415926a.
8. Fox BA, Bzik DJ. Avirulent uracil auxotrophs based on disruption of orotidine-5'-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondii. Infect Immun 2010; 78:3744-52; PMID:20605980; http://dx.doi.org/10.1128/IAI.00287-10.
9. Baird JR, Fox BA, Sanders KL, Lizotte PH, Cubillos-Ruiz JR, Scarlett UK, Rutkowski MR, Conejo-Garcia JR, Fiering S, Bzik DJ. Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. Cancer Res 2013; 73:3842-51; PMID:23704211; http://dx.doi.org/10.1158/0008-5472CAN-12-1974.
10. Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M, et al. Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. J Immunol 2013; 190:469-78; PMID:23225891; http://dx.doi.org/10.4049/jimmunol.1201209.